STOCK TITAN

Vanguard disaggregates ownership reporting for Novocure (NVCR) after realignment

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed an amendment to a Schedule 13G/A reporting beneficial ownership of 0 shares of Novocure Ltd Common Stock, representing 0% of the class.

The filing states that on January 12, 2026 Vanguard completed an internal realignment and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim and dated 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Passive ownership disclosure shows no beneficial stake after Vanguard's reorganization.

The Schedule 13G/A states amount beneficially owned: 0 and percent of class: 0%, indicating Vanguard reports no current beneficial position in Novocure Ltd. The filing ties this reporting change to an internal realignment on January 12, 2026.

Because this is a passive ownership update and not an acquisition or disposition, the practical effect depends on reporting practices of Vanguard's subsidiaries; subsequent filings by those entities may show holdings.

Reallocation of reporting responsibilities, not a trading disclosure.

The amendment relies on SEC Release No. 34-39538 to disaggregate subsidiaries that previously reported under The Vanguard Group, Inc. It explains that certain subsidiaries will report beneficial ownership separately going forward.

Watch for follow-up 13G/A or 13D/13G filings from Vanguard-affiliated entities that may reflect any actual holdings that previously appeared under the consolidated Vanguard reporting line.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does the Schedule 13G/A filed by The Vanguard Group for NVCR state?

It states The Vanguard Group reports beneficial ownership of 0 shares of Novocure Ltd, representing 0% of the class, in the submitted amendment.

Why did Vanguard change how it reports ownership for NVCR?

Vanguard completed an internal realignment on January 12, 2026 and will disaggregate certain subsidiaries’ holdings, relying on SEC Release No. 34-39538 per the amendment.

Does the amendment mean Vanguard sold NVCR shares?

No. The filing reports 0 shares beneficially owned and attributes the reporting format change to internal reorganization rather than describing any specific sale transactions.

Who signed the Schedule 13G/A amendment for NVCR and when?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with the signature dated 03/26/2026 as shown in the filing.

Will other Vanguard entities file separate disclosures for NVCR?

The amendment indicates certain Vanguard subsidiaries will report separately; subsequent filings by those entities may disclose any holdings that were previously aggregated under Vanguard.
Novocure

NASDAQ:NVCR

View NVCR Stock Overview

NVCR Rankings

NVCR Latest News

NVCR Latest SEC Filings

NVCR Stock Data

1.32B
101.90M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
Switzerland
ST. HELIER